Policy Developments - The National Medical Products Administration (NMPA) is seeking public opinions on the revised procedures for conditional approval of drug listings to improve the review and approval system [2] Drug and Device Approvals - Xuno Pharmaceutical's oral cancer drug, Abexinostat, is proposed for priority review by the NMPA, aimed at adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [5] - LuKang Pharmaceutical has received the drug registration certificate for Gefitinib tablets, a first-generation targeted drug for non-small cell lung cancer with EGFR gene mutations [6] Capital Market Activities - Shenzhen Keximingde Medical Technology Co., Ltd. completed a multi-hundred million RMB A+ round financing, with funds allocated for brand building and R&D of soft endoscope products [8] - Buchang Pharmaceutical announced the abandonment of the preferential right to acquire shares in its subsidiary, Shaanxi Modern Innovation, resulting in an 86.50% ownership stake post-transfer [9] - Taiji Group plans to optimize its equity structure by acquiring stakes in its subsidiaries for a nominal price [10] Industry Developments - Chugai Pharmaceutical and Gero PTE have signed a $220 million collaboration agreement to integrate Gero's AI-driven platform into Chugai's R&D strategy for developing therapies for age-related diseases [12] - Kanghua Biotech has terminated its collaboration with Xiran Bochuang on the development of mRNA vaccines for tuberculosis, indicating a strategic shift towards in-house R&D capabilities [13] Shareholder Activities - Guizhou Jin Domain Medical Testing Group announced that major shareholder Guochuang Kaiyuan intends to reduce its stake by up to 1% through market transactions [16] - Haichuang Pharmaceutical reported that shareholder Yingchuang Power has cumulatively reduced its stake by 0.28% [17] - Tongrentang announced the resignation of its executive vice president, Zhang Chunyou, who will continue to serve in a managerial role at a subsidiary [18]

Group 1 - The announcement indicates that Chengdu Yingchuang Power Venture Capital Co., Ltd. has reduced its shareholding in Haichuang Pharmaceutical Co., Ltd. from 6.28% to 6.00%, a decrease of 0.28% [1][2] - The reduction in shareholding was executed through centralized bidding transactions, with a total of 276,133 shares sold [1] - The reduction has triggered a change in equity that touches the 1% threshold, but the overall reduction plan has not yet been fully implemented [1][2] Group 2 - The announcement confirms that the equity change does not violate any prior commitments or plans made by the shareholder [1] - The company has disclosed that there are no other shareholders acting in concert with Chengdu Yingchuang Power Venture Capital Co., Ltd. [1] - The specific details of the share reduction plan were previously disclosed on May 14, 2025, in a separate announcement [1]

证券代码：688302 证券简称：海创药业 公告编号：2025-031 海创药业股份有限公司 关于持股5%以上股东权益变动触及1%刻度的提示性公告 信息披露义务人成都盈创动力创业投资有限公司保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 6.28% | | | | 权益变动后合计比例 | 6.00% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否 | | | 是否触发强制要约收购义务 | 是□ | 否 | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | | 其他 5%以上大股东及其一致行动人 | | 投资者的身份 | □合并口径第一大股东及其一致行动人（仅适用于无控股股东、 | | | 实际控制人） | | | □其他_/_ | ...

Investment Rating - The report does not explicitly provide an investment rating for the colorectal cancer drug industry Core Insights - Colorectal cancer is the third most common malignant tumor globally, with 2 million patients in 2023, including 537,000 in China, driving market growth due to rising incidence rates [4] - The domestic pharmaceutical industry is increasingly looking to expand internationally, with innovative drugs like furmonertinib setting benchmarks [4][18] - The market is expected to grow from 31.4 billion RMB in 2024 to 39 billion RMB by 2028, with a compound annual growth rate (CAGR) of 5.57% [8] Market Background - Colorectal cancer drug types are diverse, with treatment plans tailored to individual patient conditions [5] - The evolution of colorectal cancer drugs has seen significant advancements from the introduction of 5-FU in 1957 to the recent approval of innovative therapies [6] Market Status - The colorectal cancer drug market size increased from 22.3 billion RMB in 2019 to 29.7 billion RMB in 2023, with a CAGR of 7.43% [7][8] - The demand for treatment is urgent, with 83% of patients diagnosed at advanced stages and 44% experiencing metastasis [11] Market Competition - The competitive landscape includes a tiered structure with leading companies like Fuhong Hanlin and Meiji Pharma in the first tier, followed by others like Hengrui Medicine and Akeso [17][18] - The report highlights ten recommended brands, including Xiansheng Pharmaceutical and Weicheng Bio, which have made significant advancements in drug development [19][20][21] Development Trends - Precision therapy is becoming mainstream, with targeted and immune therapies establishing their roles in treatment [31] - Local innovative pharmaceutical companies are rapidly emerging, supported by global collaborations and comprehensive product lines [32] - Upgraded patient demands are driving innovations in service models, focusing on unmet clinical needs [33]

Core Viewpoint - The successful launch of the self-developed Class 1 anti-cancer drug, Deuteroenzalutamide, by Haichuang Pharmaceutical marks a significant milestone for the company and its mission to create effective medicines for the benefit of society [1][2]. Company Overview - Haichuang Pharmaceutical is a global innovative drug company focused on cancer and metabolic diseases, with four core technology platforms: PROTAC targeted protein degradation, deuterated drug development, targeted drug discovery and validation, and translational medicine [2]. - The company has been recognized in two national "Major New Drug Creation" science and technology projects and several provincial and municipal research projects, with eight products in development and one product already launched [2]. Product Details - Deuteroenzalutamide soft capsules are designed for adult patients with metastatic castration-resistant prostate cancer who have experienced disease progression after treatment with abiraterone acetate and chemotherapy, and who have not previously received new androgen receptor inhibitors [1]. - Prostate cancer is the second most common cancer among men globally, with 1.467 million new cases reported in 2022, and the incidence in China has been rising, with 134,000 new cases in the same year [1]. Market Launch - The product received approval from the National Medical Products Administration at the end of May and began national distribution in late June, with the first prescription issued shortly after [2]. - Patients can purchase the product at major provincial capital DTP pharmacies with a doctor's prescription, indicating its significant clinical value and urgent demand [2].

Group 1: Healthcare Legislation and Regulation - The draft of the Medical Security Law aims to establish a comprehensive basic medical insurance system and protect the rights of insured individuals [1] - The National Medical Products Administration (NMPA) held a meeting to enhance monitoring and management of medical device sales online, emphasizing risk governance and public safety [2] - Tianjin's health authorities issued a notice to promote the implementation of centralized procurement results, ensuring that selected drugs and consumables are procured within three months [3] Group 2: Medical Data and Technology - Hubei province launched a new feature for its medical insurance information platform to enable nationwide sharing of medical imaging data by 2026 [4] - The Gates Foundation announced a commitment to donate $1.6 billion to the Global Vaccine Alliance over the next five years, contributing to vaccine development and delivery [6] Group 3: Pharmaceutical Developments - Lizhu Group received approval for clinical trials of YJH-012 injection, a new siRNA drug aimed at long-term suppression of uric acid production [5] - Haisheng Pharmaceutical's HSK47388 tablet for autoimmune diseases has had its clinical trial application accepted by the NMPA [6] - Baiyue Shenzhou announced the clinical use of its bispecific HER2 inhibitor in China, targeting patients with HER2-positive biliary tract cancer [8] - Haichuang Pharmaceutical's new anti-cancer drug, Dihengzalu, has been prescribed in multiple cities, marking its entry into clinical practice [9] - Fuhong Hanlin completed the first patient dosing in Japan for its drug Hanshuang in a trial for extensive-stage small cell lung cancer [10] Group 4: Corporate Actions - Wantai Biological Pharmacy responded to investor concerns regarding the efficacy data of its 9-valent HPV vaccine, stating that the circulating data is inaccurate [12] - A senior executive at Kew Flower Pharmaceutical resigned due to retirement, effective immediately [13]

Core Insights - The article discusses the rapid restructuring of the software and information technology services industry in the Yangtze River Delta region, highlighting the competitive cluster development around industrial software [1][4] - Shanghai's government has approved measures to promote high-quality development in the software and information services sector, aiming to create a globally competitive innovation hub [1][4] - By 2024, the total revenue of the software and information services industry in the Yangtze River Delta is expected to reach 3.88 trillion yuan, accounting for nearly 30% of the national total [1][4] Group 1: Regional Development and Collaboration - Shanghai's software and information services industry revenue is projected to exceed 380 billion yuan in Q1 2025, with a year-on-year growth of 15.3%, contributing 13.6% to the city's GDP [2] - Jiangsu is focusing on the integration of software and manufacturing, with a software business revenue growth of 8.7% in 2024, and industrial software chain growth reaching 15.9% [2] - Zhejiang is building an industrial APP ecosystem with over 60,000 applications to support deep digital transformation in manufacturing [3] Group 2: Standardization and Ecosystem Integration - The Yangtze River Delta is promoting standard recognition and ecosystem integration as key strategies to break regional barriers, with a joint release of the "Yangtze River Delta Industrial Software Recommendation Directory" covering 35 quality software products [4][5] - The G60 Science and Technology Corridor is facilitating interconnectivity among 31 industrial internet platforms, reducing technical barriers for cross-regional collaboration [4] - Shanghai's "Gongfu Chain Master" platform has shared over 35,000 industrial knowledge models with Jiangsu, Zhejiang, and Anhui, fostering a collaborative model of "Shanghai R&D + Regional Application" [4] Group 3: Challenges and Future Directions - Despite progress, challenges remain in achieving ecosystem integration, including the lack of a unified regional standard system and insufficient collaborative applications in manufacturing scenarios [5][6] - The need for a standardized certification center and open-source platform is emphasized to enhance cross-regional collaboration and build a foundational trust mechanism [5][6] - The article suggests that the ability to establish an efficient and unified collaborative mechanism will directly impact the Yangtze River Delta's competitiveness in the global software and information services industry [6]

Group 1 - The core point of the news is that Haichuang Pharmaceutical has launched its self-developed Class I anti-cancer drug, Deuteroenzalutamide soft capsules, which are now available nationwide for patients with metastatic castration-resistant prostate cancer [1][2] - The drug is specifically designed for adult patients who have progressed after treatment with Abiraterone acetate and chemotherapy, and who have not previously received new androgen receptor inhibitors [1] - Prostate cancer is the second most common cancer among men globally, with 1.467 million new cases reported in 2022, and China saw 134,000 new cases in the same year, indicating a rising trend in incidence [1] Group 2 - Deuteroenzalutamide soft capsules are the first innovative drug approved in China for patients with metastatic castration-resistant prostate cancer, highlighting its clinical significance and urgent demand [1][2] - The company emphasizes its commitment to ensuring the quality and stable supply of the drug while accelerating the development of its rich pipeline of innovative therapies for global patients [2] - The drug reportedly shows superior safety compared to other endocrine therapies, significantly reducing the incidence of central nervous system adverse events and common complications in elderly patients [1]

金十数据6月19日讯，科创板累计已有54家未盈利企业上市。目前已有22家企业上市后实现盈利，还有 32家尚未实现摘"U"。根据《科创成长层指引》要求，上述32家公司将自指引（正式稿）发布之日起纳 入科创成长层。具体来看，32家尚未摘"U"的存量公司包括：泽璟制药、君实生物、前沿生物、青云科 技、和辉光电、精进电动、百济神州、迪哲医药、迈威生物、翱捷科技、亚虹医药、首药控股、海创药 业、云从科技、益方生物、奥比中光、盟科药业、诺诚健华、信科移动、星环科技、裕太微、云天励 飞、天智航、奇安信、寒武纪、亿华通、埃夫特、慧智微、芯联集成、智翔金泰、盛科通信、中巨芯。 （上证报） 32家科创板未盈利公司将纳入科创成长层 ...

Core Viewpoint - The Chinese innovative pharmaceutical industry is experiencing a significant transformation, marked by increased research breakthroughs, active business development (BD) transactions, and a shift in market perception, moving away from the "me too" label associated with Chinese drugs [1][5][10] Market Performance - The innovative pharmaceutical sector has seen a strong resurgence in the secondary market, with A-share and Hong Kong stock indices rising significantly; A-share innovative drug stocks increased by 34.27% and Hong Kong's innovative drug index surged over 70% from April 8 to June 16 [3] - The sector had previously undergone a four-year adjustment period, with the Hang Seng Innovative Drug Index hitting a historical low in July 2023, down over 70% from July 2021 [3] - The recovery is driven by active BD transactions and the commercialization of innovative drugs, with a notable shift in market sentiment towards the sector [3][4] Business Development Trends - Numerous Chinese innovative drug companies have announced significant BD projects in cutting-edge fields, with notable transactions including a $12.5 billion upfront payment from Pfizer to 3SBio for a PD-1/VEGF dual antibody [5] - The License-out model has become a primary funding source for unprofitable innovative drug companies, with Q1 2025 seeing a record 41 transactions totaling $369.29 billion, surpassing the total for the first half of 2024 [6] - The ability of Chinese companies to leverage their research platforms and enhance capital efficiency is reshaping the traditional high-risk, high-investment model of the industry [6] Commercialization and Profitability - The commercialization of innovative drugs is gaining momentum, with 20 new class 1 innovative drugs approved in the first five months of 2023, marking a five-year high [7] - Companies like BeiGene are expected to achieve positive operating profits by 2025, indicating a shift from the traditional "burning cash" phase to profitability [7][8] - The improved financial health of innovative drug companies enhances their negotiating power in BD transactions, allowing them to demand better terms [8] Competitive Landscape - The competition in the innovative drug sector is intensifying, with a focus on efficiency across the entire drug development chain, from target discovery to commercialization [9] - The majority of BD transactions are concentrated in the oncology sector, particularly in ADC and dual antibody technologies, leading to increased competition and market saturation [9] - Companies are encouraged to innovate and differentiate their products to avoid the pitfalls of homogeneity and to enhance their global competitiveness [9] Challenges Ahead - Despite the progress, the high failure rate in new drug development remains a significant challenge, particularly for early-stage research [10] - There is a growing expectation among investors for innovative drug companies to not only achieve profitability but also to provide stable dividends in the future [10]